Tenax Therapeutics, Inc. (TENX) income statement
TENXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$1.43+0.01 (+0.70%)
Close on Nov 18, 2026Market cap $53.52MP/E –Yield –
Tenax Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -55.6%
Financial strength
- Current ratio
- 15.07
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 1461.7%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.47
- Dividend yield
- –
See a number that looks wrong?